Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Kidney Neoplasms 3Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Urologic Neoplasms 1Urogenital Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Gliosarcoma 1Glioblastoma 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Sunitinib 64Nivolumab 54Sorafenib 38Bevacizumab 35Axitinib 35pembrolizumab 34Everolimus 30cabozantinib 29pazopanib 26aldesleukin 26Ipilimumab 23Interleukin-2 19Specimen Handling 17Magnetic Resonance Spectroscopy 17Gemcitabine 17lenvatinib 16Interferon-alpha 15Interferon alpha-2 13Radiosurgery 12Cyclophosphamide 12fludarabine phosphate 11atezolizumab 10durvalumab 8Introns 8Erlotinib Hydrochloride 8Biopsy 8temsirolimus 7avelumab 7Radiotherapy 7Capecitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Renal Cell × motexafin gadolinium × Clear all
NCT00717587 2014-01-10

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00134186 2007-03-05

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

Pharmacyclics LLC.

Phase 2 Completed
43 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡